Skip to content
This randomised control trial aims to determine whether early commencement of a sequential schedule of two pneumococcal conjugate vaccines, Pneumococcal Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV or Synflorix) and 13-valent pneumococcal conjugate vaccine (PCV13 or Prevenar13), given in sequence at one, two, four (PHiD-CV), and 6 months (PCV13), gives greater protection against otitis media compared to either PCV13-alone or PHiD-CV-alone at two, four, and six months.
The project also aims to determine if a combination of pneumococcal vaccines is superior to single vaccines in terms of immunogenicity, nasopharyngeal carriage of otitis media pathogens, and all-cause otitis media in Indigenous infants living in remote communities.
The project is funded by the National Health and Medical Research Council (NHMRC), and is headed by Menzies School of Health Research.
Associate Professor Amanda Leach
Menzies School of Health Research
John Mathews Building
Royal Darwin Hospital Campus
Casuarina NT 0810
PO Box 41096
Casuarina NT 0811